Compare ADMA Biologics Inc (ADMA) vs Deutsche Bank AG (DB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Deutsche Bank AG — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Deutsche Bank AG trades at $35.09 (market cap $70.38B). The key difference: Deutsche Bank AG is far larger — about 33× ADMA Biologics Inc's market cap, and Deutsche Bank AG pays a 3.17% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | DB | |
|---|---|---|
Market Cap | $2.13B | $70.38B |
Sector | Health | Financials |
52-Week High | $20.38 | $40.33 |
52-Week Low | $7.60 | $28.37 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Deutsche Bank (DB) trades at $36.64, up 2.18% today, with bullish technical signals from moving averages and ADX indicators. The stock shows strong fundamental momentum with three consecutive quarterly EPS beats and a net income margin of 21.98% for 2025. Recent strategic moves include selling its India retail unit to Kotak to sharpen focus on higher-growth businesses, while maintaining a dividend payout of $1.00 for H1-26.
The outlook remains positive with revenue growth to $32.2B projected for 2026 and a profit margin of 21.97%. Investment opportunities include attractive valuation with P/E of 10.29 and P/B of 0.8, but risks involve negative operating cash flow of -$28.58B in 2024 and competitive pressures from JPMorgan's expansion in Germany.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
